TickerFacts.

uniQure N.V. (QURE): Cost of Revenue

Annual figures by period end, from SEC filings.

$1.69M
Year ended 2025-12-31
$1.71M
Trailing 12 months to 2026-03-31
+10.4%
3-year compound annual growth
-10.3%
5-year compound annual growth
$24.98M2016-12-31: $1.35M2017-12-31: $817.0K2018-12-31: $1.20M2019-12-31: $1.65M2020-12-31: $2.90M2021-12-31: $24.98M2022-12-31: $1.25M2023-12-31: $65.0K2024-12-31: $1.27M2025-12-31: $1.69M$1.69M
2016-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$1.69M+33.1%2026-03-02, From 2025-01-01
2024-12-31$1.27Mn/m2026-03-02, From 2024-01-01
2023-12-31$65.0K-94.8%2026-03-02, From 2023-01-01
2022-12-31$1.25M-95.0%2025-02-27, From 2022-01-01
2021-12-31$24.98M+761.5%2024-02-28, From 2021-01-01
2020-12-31$2.90M+75.3%2021-03-01, From 2020-01-01
2019-12-31$1.65M+37.6%2021-03-01, From 2019-01-01
2018-12-31$1.20M+47.1%2021-03-01, From 2018-01-01
2017-12-31$817.0K-39.4%2020-03-02, From 2017-01-01
2016-12-31$1.35Mn/a2019-02-28, From 2016-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
uniQure N.V. (QURE)2025-12-31$1.69M+33.1%
Pyxis Oncology, Inc. (PYXS)2025-12-31$2.39M+402.7%
CV Sciences, Inc. (CVSI)2025-12-31$7.04M-17.6%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$6.64M-14.5%
Evofem Biosciences, Inc. (EVFM)2025-12-31$4.62M+20.4%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$10.64M-38.8%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$857.0K-28.6%
Jaguar Health, Inc. (JAGX)2025-12-31$3.77M+93.0%
Celularity Inc (CELU)2025-12-31$20.07M+33.9%

Compare QURE, PYXS, CVSI, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗